GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Turk Ilac ve Serum Sanayi (IST:TRILC) » Definitions » EV-to-EBIT

Turk Ilac ve Serumnayi (IST:TRILC) EV-to-EBIT : 22.83 (As of May. 27, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Turk Ilac ve Serumnayi EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Turk Ilac ve Serumnayi's Enterprise Value is ₺5,139 Mil. Turk Ilac ve Serumnayi's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was ₺225 Mil. Therefore, Turk Ilac ve Serumnayi's EV-to-EBIT for today is 22.83.

The historical rank and industry rank for Turk Ilac ve Serumnayi's EV-to-EBIT or its related term are showing as below:

IST:TRILC' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.21   Med: 17.2   Max: 56.69
Current: 22.83

During the past 6 years, the highest EV-to-EBIT of Turk Ilac ve Serumnayi was 56.69. The lowest was 9.21. And the median was 17.20.

IST:TRILC's EV-to-EBIT is ranked worse than
62.35% of 672 companies
in the Drug Manufacturers industry
Industry Median: 16.985 vs IST:TRILC: 22.83

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Turk Ilac ve Serumnayi's Enterprise Value for the quarter that ended in Sep. 2023 was ₺2,843 Mil. Turk Ilac ve Serumnayi's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was ₺225 Mil. Turk Ilac ve Serumnayi's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 7.92%.


Turk Ilac ve Serumnayi EV-to-EBIT Historical Data

The historical data trend for Turk Ilac ve Serumnayi's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Turk Ilac ve Serumnayi EV-to-EBIT Chart

Turk Ilac ve Serumnayi Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBIT
Get a 7-Day Free Trial - - - 25.91 14.94

Turk Ilac ve Serumnayi Quarterly Data
Dec17 Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.20 14.94 9.74 9.25 12.63

Competitive Comparison of Turk Ilac ve Serumnayi's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Turk Ilac ve Serumnayi's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Turk Ilac ve Serumnayi's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Turk Ilac ve Serumnayi's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Turk Ilac ve Serumnayi's EV-to-EBIT falls into.



Turk Ilac ve Serumnayi EV-to-EBIT Calculation

Turk Ilac ve Serumnayi's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=5138.925/225.102
=22.83

Turk Ilac ve Serumnayi's current Enterprise Value is ₺5,139 Mil.
Turk Ilac ve Serumnayi's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺225 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Turk Ilac ve Serumnayi  (IST:TRILC) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Turk Ilac ve Serumnayi's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2023 ) =EBIT / Enterprise Value (Q: Sep. 2023 )
=225.102/2842.91215
=7.92 %

Turk Ilac ve Serumnayi's Enterprise Value for the quarter that ended in Sep. 2023 was ₺2,843 Mil.
Turk Ilac ve Serumnayi's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺225 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Turk Ilac ve Serumnayi EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Turk Ilac ve Serumnayi's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Turk Ilac ve Serumnayi (IST:TRILC) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Bügduz Mah. Enver Pasa Cad., No: 8 Akyurt, Ankara, TUR, TR 06750
Turk Ilac ve Serum Sanayi is engaged in the production of human pharmaceuticals and vaccines.

Turk Ilac ve Serumnayi (IST:TRILC) Headlines

No Headlines